These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9462437)

  • 1. In-vitro selection of HIV-1 variants resistant to non-nucleoside reverse transcriptase inhibitors in monocyte-derived macrophages.
    Been-Tiktak AM; de Haas CJ; de Graaf L; Boucher CA; Verhoef J; Borleffs JC; Nottet HS; Schuurman R
    J Antimicrob Chemother; 1997 Dec; 40(6):847-53. PubMed ID: 9462437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
    Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
    Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.
    Witvrouw M; Pannecouque C; Van Laethem K; Desmyter J; De Clercq E; Vandamme AM
    AIDS; 1999 Aug; 13(12):1477-83. PubMed ID: 10465070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
    Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
    J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.
    Romero DL; Olmsted RA; Poel TJ; Morge RA; Biles C; Keiser BJ; Kopta LA; Friis JM; Hosley JD; Stefanski KJ; Wishka DG; Evans DB; Morris J; Stehle RG; Sharma SK; Yagi Y; Voorman RL; Adams WJ; Tarpley WG; Thomas RC
    J Med Chem; 1996 Sep; 39(19):3769-89. PubMed ID: 8809165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).
    Demeter LM; Shafer RW; Meehan PM; Holden-Wiltse J; Fischl MA; Freimuth WW; Para MF; Reichman RC
    Antimicrob Agents Chemother; 2000 Mar; 44(3):794-7. PubMed ID: 10681363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
    J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.
    Huang W; Gamarnik A; Limoli K; Petropoulos CJ; Whitcomb JM
    J Virol; 2003 Jan; 77(2):1512-23. PubMed ID: 12502865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
    Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
    J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.
    de Ronde A; van Dooren M; van Der Hoek L; Bouwhuis D; de Rooij E; van Gemen B; de Boer R; Goudsmit J
    J Virol; 2001 Jan; 75(2):595-602. PubMed ID: 11134272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
    Cao YL; Li SX; Chen H; Guo Y
    Yao Xue Xue Bao; 2009 Apr; 44(4):355-61. PubMed ID: 19545051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.
    Uhlmann EJ; Tebas P; Storch GA; Powderly WG; Lie YS; Whitcomb JM; Hellmann NS; Arens MQ
    J Clin Virol; 2004 Nov; 31(3):198-203. PubMed ID: 15465412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
    Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY; Vrang L; Oberg B; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.
    Mas A; Parera M; Briones C; Soriano V; Martínez MA; Domingo E; Menéndez-Arias L
    EMBO J; 2000 Nov; 19(21):5752-61. PubMed ID: 11060026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
    Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
    Antivir Chem Chemother; 1999 Sep; 10(5):233-40. PubMed ID: 10574178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.